全文获取类型
收费全文 | 198102篇 |
免费 | 4322篇 |
国内免费 | 443篇 |
专业分类
耳鼻咽喉 | 2778篇 |
儿科学 | 7469篇 |
妇产科学 | 5928篇 |
基础医学 | 25757篇 |
口腔科学 | 5769篇 |
临床医学 | 15590篇 |
内科学 | 35885篇 |
皮肤病学 | 4755篇 |
神经病学 | 11953篇 |
特种医学 | 10843篇 |
外国民族医学 | 98篇 |
外科学 | 29805篇 |
综合类 | 1088篇 |
一般理论 | 5篇 |
预防医学 | 16357篇 |
眼科学 | 4333篇 |
药学 | 13694篇 |
2篇 | |
中国医学 | 140篇 |
肿瘤学 | 10618篇 |
出版年
2018年 | 3739篇 |
2017年 | 3988篇 |
2016年 | 3323篇 |
2015年 | 5010篇 |
2014年 | 4493篇 |
2013年 | 3631篇 |
2012年 | 10177篇 |
2011年 | 5004篇 |
2010年 | 2386篇 |
2009年 | 3978篇 |
2008年 | 2222篇 |
2007年 | 2916篇 |
2006年 | 3145篇 |
2005年 | 11241篇 |
2004年 | 12735篇 |
2003年 | 8281篇 |
2002年 | 3494篇 |
2001年 | 4362篇 |
2000年 | 1730篇 |
1999年 | 5874篇 |
1998年 | 527篇 |
1995年 | 392篇 |
1992年 | 6886篇 |
1991年 | 7128篇 |
1990年 | 7380篇 |
1989年 | 6963篇 |
1988年 | 6487篇 |
1987年 | 6259篇 |
1986年 | 5968篇 |
1985年 | 5267篇 |
1984年 | 3605篇 |
1983年 | 2918篇 |
1982年 | 1003篇 |
1981年 | 772篇 |
1980年 | 836篇 |
1979年 | 3842篇 |
1978年 | 2368篇 |
1977年 | 1783篇 |
1976年 | 1564篇 |
1975年 | 2481篇 |
1974年 | 3110篇 |
1973年 | 2742篇 |
1972年 | 2762篇 |
1971年 | 2746篇 |
1970年 | 2560篇 |
1969年 | 2466篇 |
1968年 | 2237篇 |
1967年 | 2165篇 |
1966年 | 1898篇 |
1965年 | 1131篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
2.
3.
4.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
5.
<正>what is the rationale for immunotherapies in Parkinsonian syndromes(PS)? PS are neurodegenerative diseases which are clinically characterized by a hypokinetic phenotype in combination with additional motor and non-motor symptoms. One major patholog- 相似文献
6.
7.
Emilie Cayssials MD Jose Torregrosa-Diaz MD Pilar Gallego-Hernanz MD Florence Tartarin MD Thomas Systchenko MD Natacha Maillard MD Déborah Desmier MD Antoine Machet MD Emmanuel Fleck MD Anne Corby MD Carine Motard MD Guillaume Denis MD André Herbelin PhD Jean-Marc Gombert MD PhD Lydia Roy MD Stéphanie Ragot PharmD PhD Xavier Leleu MD PhD François Guilhot MD Jean-Claude Chomel PharmD PhD 《Cancer》2020,126(15):3438-3447
8.
Diamantis I. Tsilimigras MD Rittal Mehta MPH Alfredo Guglielmi MD Francesca Ratti MD Hugo P. Marques MD Olivier Soubrane MD Vincent Lam MD George A. Poultsides MD Irinel Popescu MD Sorin Alexandrescu MD Guillaume Martel MD Tom Hugh MD Luca Aldrighetti MD Itaru Endo MD PhD Timothy M. Pawlik MD MPH PhD FACS FRACS 《Journal of surgical oncology》2020,122(5):955-963
9.
10.
Accuracy and Precision of an Ultrasound-Based Device to Measure the Pelvic Tilt in Several Positions